Daré Bioscience, Inc.
DARE
$0.72
$0.011.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7,817.51% | 4,368.34% | 10,412.24% | -103.04% | -100.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7,817.51% | 4,368.34% | 10,412.24% | -103.04% | -100.62% |
| Cost of Revenue | 56.98% | 81.68% | 106.00% | -122.01% | -118.31% |
| Gross Profit | -26.79% | -62.54% | -85.14% | 123.39% | 120.58% |
| SG&A Expenses | 2.22% | -1.04% | -4.29% | -9.22% | -18.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.42% | -40.43% | -37.84% | -30.12% | -37.61% |
| Operating Income | 39.87% | 45.62% | 42.21% | 24.16% | 30.92% |
| Income Before Tax | 40.94% | -617.02% | -230.55% | -384.47% | -158.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.94% | -617.02% | -230.55% | -384.47% | -158.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.94% | -617.02% | -230.55% | -384.47% | -158.33% |
| EBIT | 39.87% | 45.62% | 42.21% | 24.16% | 30.92% |
| EBITDA | 49.71% | 54.39% | 49.14% | 28.87% | 33.22% |
| EPS Basic | 64.06% | -413.13% | -161.76% | -271.97% | -106.91% |
| Normalized Basic EPS | 64.06% | -412.87% | -161.65% | -292.79% | -112.41% |
| EPS Diluted | 59.47% | -417.69% | -172.21% | -259.64% | -103.59% |
| Normalized Diluted EPS | 64.06% | -384.93% | -155.79% | -283.62% | -110.03% |
| Average Basic Shares Outstanding | 65.15% | 49.55% | 33.98% | 17.74% | 7.94% |
| Average Diluted Shares Outstanding | 65.15% | 49.26% | 33.72% | 17.51% | 7.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |